Your browser doesn't support javascript.
loading
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
McInnes, Iain B; Mease, Philip J; Ritchlin, Christopher T; Rahman, Proton; Gottlieb, Alice B; Kirkham, Bruce; Kajekar, Radhika; Delicha, Eumorphia-Maria; Pricop, Luminita; Mpofu, Shephard.
Afiliação
  • McInnes IB; Institute of Infection Immunity and Inflammation, University of Glasgow, Glasgow, UK.
  • Mease PJ; Division of Rheumatology Clinical Research, Swedish Medical Centre and University of Washington, Seattle, WA.
  • Ritchlin CT; Allergy/Immunology and Rheumatology Division, University of Rochester, Rochester, NY, USA.
  • Rahman P; Faculty of Medicine, Memorial University, St. John's, NL, Canada.
  • Gottlieb AB; Department of Dermatology, New York Medical College, Valhalla, NY, USA.
  • Kirkham B; Rheumatology Department, Guy's & St Thomas' NHS Foundation Trust, London, UK.
  • Kajekar R; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Delicha EM; Novartis Pharma, Basel, Switzerland.
  • Pricop L; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Mpofu S; Novartis Pharma, Basel, Switzerland.
Rheumatology (Oxford) ; 56(11): 1993-2003, 2017 11 01.
Article em En | MEDLINE | ID: mdl-28968735

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite Psoriásica / Antirreumáticos / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Artrite Psoriásica / Antirreumáticos / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article